{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:55Z","timestamp":1789556575413,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Portal vein tumor thrombus (PVTT) is a major manifestation of macrovascular invasion in hepatocellular carcinoma (HCC) and is associated with aggressive progression and heterogeneous responses to immune checkpoint inhibitor\u2013based therapy. Current stratification relies mainly on anatomical extent, liver function, and tumor burden and does not fully capture the biology of the intravascular lesion. In this Review, we propose PVTT as an anatomically distinct, lesion-centered intravascular tumor\u2013immune niche for hypothesis generation rather than as an established autonomous immune compartment. We distinguish PVTT-direct evidence from supportive venous-thrombus\/metastatic evidence and HCC-extrapolated mechanisms. Current PVTT-direct evidence is strongest for clonal and spatial divergence and PVTT-specific stromal remodeling, including myofibroblast-like cancer-associated fibroblast accumulation, NID1-associated immune barriers, and FAP-positive fibroblast\/GJA5-positive endothelial hubs. Venous-thrombus studies provide supportive evidence for macrophage-associated immune suppression, including C5aR-positive tumor-associated macrophages, whereas hypoxia\u2013adenosine signaling, adaptive checkpoint activation, and lipid metabolic rewiring remain largely extrapolated candidate mechanisms requiring direct PVTT validation. On this basis, we organize the available evidence into literature-informed candidate resistance phenotypes and outline a translational framework integrating paired primary tumor\u2013PVTT sampling, spatial and single-cell profiling, functional imaging, and liquid biopsy. These phenotypes are conceptual groupings rather than empirically derived or validated patient subtypes and should guide mechanistic testing and biomarker-enriched trial design rather than routine treatment assignment. Prospective PVTT-specific studies with anatomically resolved sampling, longitudinal pharmacodynamic assessment, and biomarker-by-treatment interaction analyses are required to determine whether this lesion-centered niche framework can ultimately provide clinically useful stratification.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1946103","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:13:21Z","timestamp":1789553601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune escape in portal vein tumor thrombus: an intravascular tumor\u2013immune niche framework for hepatocellular carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Xingfei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Peking University Research Center for Diagnosis & Treatment of Liver Cancer","place":["Beijing, China"]},{"name":"Peking University Institute of Organ Transplantation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Peking University Research Center for Diagnosis & Treatment of Liver Cancer","place":["Beijing, China"]},{"name":"Peking University Institute of Organ Transplantation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigao","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Peking University Research Center for Diagnosis & Treatment of Liver Cancer","place":["Beijing, China"]},{"name":"Peking University Institute of Organ Transplantation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Peking University Research Center for Diagnosis & Treatment of Liver Cancer","place":["Beijing, China"]},{"name":"Peking University Institute of Organ Transplantation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Peking University Research Center for Diagnosis & Treatment of Liver Cancer","place":["Beijing, China"]},{"name":"Peking University Institute of Organ Transplantation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s318070","article-title":"Portal vein tumor thrombosis and hepatocellular carcinoma \u2013 the changing tides","volume":"8","author":"Khan","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040627","article-title":"Immunotherapy in hepatocellular carcinoma with portal vein tumour thrombosis: from poor prognosis to curative-intent strategies","volume":"18","author":"Marzi","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3760\/cma.j.cn112137-20251211-03271","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2026 edition) [in Chinese","volume":"106","year":"2026","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112626","article-title":"Evolving treatment of advanced hepatocellular carcinoma in the Asia\u2013Pacific region: a review and multidisciplinary expert opinion","volume":"13","author":"Ogasawara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02845-9","article-title":"Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis","volume":"70","author":"Tsai","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1038\/s41467-022-32283-3","article-title":"A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-021-01036-y","article-title":"Clonal evolution in liver cancer at single-cell and single-variant resolution","volume":"14","author":"Su","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-026-01307-2","article-title":"Large-scale single-cell analysis and in silico perturbation reveal dynamic evolution of HCC: from initiation to therapeutic targeting","volume":"10","author":"Xia","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001182","article-title":"Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution","volume":"82","author":"Zhou","year":"2025","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.34133\/research.1161","article-title":"Repurposed acarbose targets nidogen-1 to remodel the tumor stroma and suppress portal vein tumor thrombus in hepatocellular carcinoma","volume":"9","author":"Han","year":"2026","journal-title":"Res (Wash D C)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.fmre.2026.05.011","article-title":"Single-cell multi-omics reveal epigenomic reprogramming and multicellular ecosystem shaping venous tumor thrombus in hepatocellular carcinoma","author":"Chen","year":"2026","journal-title":"Fundam Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","article-title":"Amplification of spatially isolated adenosine pathway by tumor\u2013macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-3453","article-title":"Hepatitis B\u2013induced IL8 promotes hepatocellular carcinoma venous metastasis and intrahepatic Treg accumulation","volume":"81","author":"Zhang","year":"2021","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12964-023-01200-6","article-title":"Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling","volume":"21","author":"Sun","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg3750","article-title":"Comprehensive analysis of spatial architecture in primary liver cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215448","article-title":"Intrinsic and extrinsic control of hepatocellular carcinoma by TAM receptors","volume":"13","author":"Hedrich","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-00931-z","article-title":"CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance","volume":"47","author":"Coursier","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092687","article-title":"Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours: mechanisms and therapeutic opportunities","volume":"12","author":"Freeman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents \u2014 overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-1693","article-title":"Long-chain fatty acid redistribution induced by SLC27A2 deficiency facilitates hypoxic adaptation and immunosuppression in hepatocellular carcinoma","volume":"85","author":"Fu","year":"2025","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09297-0","article-title":"ACLY inhibition promotes tumour immunity and suppresses liver cancer","volume":"645","author":"Gautam","year":"2025","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12935-021-02108-2","article-title":"Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218205","article-title":"G6PD+CSV+ circulating tumor cells associated with portal vein tumor thrombus formation via EMT-ferroptosis crosstalk: a dual biomarker for therapeutic efficacy and prognosis prediction in hepatocellular carcinoma","volume":"639","author":"Chen","year":"2026","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01758","article-title":"Circulating tumor-cell-associated white blood cell clusters in peripheral blood indicate poor prognosis in patients with hepatocellular carcinoma","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","article-title":"Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i17.3122","article-title":"Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal\/hepatic vein tumor thrombosis","volume":"23","author":"Li","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174334","article-title":"Liquid biopsy in hepatocellular carcinoma: opportunities and challenges for immunotherapy","volume":"13","author":"Maravelia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s452688","article-title":"Development and validation of a novel prognostic nomogram based on platelet and CD8+T cell counts in hepatocellular carcinoma patients with portal vein tumor thrombosis","volume":"11","author":"Shi","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.44024","article-title":"Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma","volume":"16","author":"Wu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-019-1043-x","article-title":"Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA","volume":"18","author":"Ye","year":"2019","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000001422","article-title":"Prognostic value of FDG uptake of portal vein tumor thrombosis in patients with locally advanced hepatocellular carcinoma","volume":"42","author":"Lee","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00876-x","article-title":"Spatial multi-omics mapping of tumor microanatomy dynamics following radiotherapy combined with targeted-immunotherapy in hepatocellular carcinoma","volume":"14","author":"Ji","year":"2026","journal-title":"biomark Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2592","article-title":"Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s432542","article-title":"Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241231252","article-title":"Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"16","author":"Li","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1374149","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1165","article-title":"Efficacy of lenvatinib combined with anti\u2013PD-1 antibodies plus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective, multicenter study","volume":"56","author":"Ou","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000581","article-title":"Transarterial chemoembolization combined with apatinib plus PD-1 inhibitors for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study","volume":"14","author":"Xia","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03511-6","article-title":"Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study","volume":"72","author":"Yu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf439","article-title":"Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus","volume":"31","author":"Zhou","year":"2026","journal-title":"Oncologist"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413590","article-title":"Immune microenvironment and the effect of vascular endothelial growth factor inhibition in hepatocellular carcinoma","volume":"25","author":"Oura","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000539897","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010061","article-title":"Tumor-associated macrophage targeting of nanomedicines in cancer therapy","volume":"16","author":"Kang","year":"2024","journal-title":"Pharmaceutics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030392","article-title":"Therapeutic approaches targeting proteins in tumor-associated macrophages and their applications in cancers","volume":"12","author":"Wu","year":"2022","journal-title":"Biomolecules"},{"key":"B54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.21037\/jgo-21-162","article-title":"Transcriptome sequencing-based personalized analysis of hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"12","author":"Qiu","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414121","article-title":"Single-cell and bulk transcriptomic datasets enable the development of prognostic models based on dynamic changes in the tumor immune microenvironment in patients with hepatocellular carcinoma and portal vein tumor thrombus","volume":"15","author":"Tong","year":"2024","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.08.022","article-title":"Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma","volume":"58","author":"Jiang","year":"2013","journal-title":"J Hepatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11902-9","article-title":"Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study","volume":"36","author":"Li","year":"2026","journal-title":"Eur Radiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1946103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:13:23Z","timestamp":1789553603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1946103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1946103"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1946103","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1946103"}}